Doctor Who Fought 8 Years for Children’s Lives Now Hit with Legal Notice
Hyderabad paediatrician Dr. Sivaranjani Santosh, who advocated for clearer ORS labelling, receives legal notice from companies linked to Kenvue and Johnson & Johnson.
Table of contents [Show]
The recent Supreme Court judgment
The recent Supreme Court judgment in the case of M/s SBS Biotech & Others v. State of Himachal Pradesh (delivered on February 20, 2026, cited as 2026 INSC 171) serves as a stark reminder of the strict regulatory scrutiny facing India’s pharmaceutical industry. In a ruling that upholds the continuation of criminal prosecution under the Drugs and Cosmetics Act, 1940, the Apex Court dismissed the appeal by Himachal Pradesh-based pharma firm SBS Biotech and its officials, reinforcing that serious lapses in manufacturing practices and record-keeping are not mere technicalities they attract grave consequences.
Background of the Case
SBS Biotech, a partnership firm operating in Kala Amb, Himachal Pradesh one of India’s key pharmaceutical manufacturing hubs came under the radar following inspections by drug authorities.
• On July 22, 2014, a Drug Inspector conducted an initial inspection.
• A follow-up re-inspection occurred on August 5, 2014.
The authorities alleged multiple contraventions, primarily related to:
• Non-maintenance or failure to produce statutory records (as required under Rules like 74, 22(1)(cca), 18-B, and Schedule M of the Drugs and Cosmetics Rules, 1945).
• Breaches in good manufacturing practices (GMP), particularly concerning controlled substances or habit-forming drug inputs like Pseudoephedrine.
• Violations linked to manufacturing, distribution, and batch production records.
These lapses led to charges under Sections 18(a)(vi) read with Section 27(d) (for prohibited manufacture/sale/contravention) and Section 28-A of the Act offences that carry significant penalties, including imprisonment.
A complaint was filed in 2017, initiating criminal proceedings. The firm approached the Himachal Pradesh High Court seeking to quash the proceedings (via Cr. MMO No. 167 of 2018), but the High Court refused relief in 2024. The matter then reached the Supreme Court via a special leave petition.
The Supreme Court’s Key Holdings
A bench comprising Justices Prashant Kumar Mishra and Vipul M. Pancholi delivered the judgment, making several important clarifications:
- Trial Jurisdiction: Offences punishable under Chapter IV of the Act (which includes manufacturing and related violations) must be tried by a court not inferior to a Sessions Court when Section 32(2) applies. The summary trial provision under Section 36-A cannot override this requirement. The Court rejected the appellants’ argument for a summary trial by a Magistrate, upholding the committal to a Special Judge/Sessions Court.
- Sustainability of the Complaint: The allegations of non-maintenance/non-production of records and GMP violations were held to be legally valid and not frivolous. The Court found no grounds to interfere with the prosecution at this stage.
- No Quashing on Technical Grounds: The firm raised procedural defenses, but the Supreme Court emphasized that such serious regulatory breaches warrant full trial rather than early dismissal.
The result? The criminal appeal was dismissed, and the prosecution can proceed potentially leading to trial on merits.
Why This Ruling Matters for the Pharma Sector
Himachal Pradesh hosts hundreds of pharma units, many focused on generics and APIs. Cases like this highlight ongoing enforcement priorities:
• Record-Keeping as Core Compliance Documentation isn’t “paperwork”; it’s a substantive requirement. Failures here can trigger criminal liability under Sections 27(d) and 28-A, not just administrative penalties.
• GMP Enforcement Post-COVID and amid global scrutiny (e.g., cough syrup export issues), regulators are vigilant about manufacturing standards.
• No Easy Escape via Procedure Pharma companies cannot halt cases through quashing petitions on jurisdictional or summary trial arguments when Section 32(2) mandates Sessions-level trial.
• Limitation and Timelines While not the central issue here, related rulings clarify that limitation periods (e.g., under CrPC) start when full accused identity is known, giving authorities flexibility.
This decision aligns with the judiciary’s broader push for accountability in the pharma space especially after incidents damaging India’s export reputation.
Implications and Takeaways
For pharma manufacturers, especially in clusters like Baddi-Kala Amb:
• Prioritize robust documentation systems, regular internal audits, and GMP training.
• Treat inspections seriously non-production of records can be as damaging as quality failures.
• Legal teams should note: Technical defenses on trial procedure may not succeed when core Chapter IV offences are involved.
For regulators and the public, it reinforces that the Drugs and Cosmetics Act is a criminal statute with teeth, designed to protect health and ensure quality.
The pharma industry thrives on innovation and access but only when built on unshakeable compliance. This Supreme Court ruling is a clear signal: regulatory shortcuts will not be tolerated.
As India’s drug sector grows globally, judgments like this help maintain standards and trust. What are your views on stricter enforcement versus the challenges faced by smaller manufacturers?
Share in the comments.
Sources: Supreme Court judgment (indiankanoon.org, Verdictum.in, LiveLaw), Medical Dialogues (March 6, 2026 report), CourtBook.in, and related legal analyses (as of March 7, 2026).
